Addressing E6(R2) as an SMB: Why small pharma and emerging biotechs may be falling behind

Posted by Cheryle Evans on 6/11/19 2:17 PM

It’s been three years since ICH added the E6(R2) addendum to its Good Clinical Practice guidelines. The addendum was intended to create harmonization between US and EU clinical research regulations, and to drive adoption of quality risk management methodologies in clinical trial design, conduct, and oversight.

Implications of the E6(R2) Addendum

To achieve compliance, sponsors must implement an end-to-end risk-based monitoring approach across all aspects of clinical research that will proactively assess trends, identify gaps, isolate outlier data, and then plan appropriate mitigations to address the issues.

This approach leverages data management and aggregation to proactively identify risks, which improves the safety and effectiveness of the clinical oversight process, while making better use of monitoring resources. However, achieving this proactive risk environment requires a significant investment in technology, training, and change management to adapt Standard Operating Procedures (SOPs), which can be a complex, long, and costly endeavor.

Most large pharma organizations and CROs have already achieved compliance. However, smaller and mid-sized biopharma firms (SMBs), where novel and innovative research is occurring, have been slower to make these changes, which could be placing their important research at risk.

E6(R2): Risk Assessment

E6(R2) requires more than just adopting a new data management platform – though that is part of the approach. Pharma, biotech and device manufacturers also have to establish formal oversight steps for vendors to verify adherence to quality risk management steps at every stage of the clinical research lifecycle, and be able to prove to auditors that these steps are being consistently followed.

Many SMBs lack the expertise, infrastructure, SOPs and resources to make these changes, while others aren’t aware of the extent of changes required, or they begin too late in planning to develop an effective RBM approach. These delays put them at a higher risk of audit findings for inadequate monitoring or lack of proof that risk processes are being followed. For example auditors may find that risk assessments were not considered or implemented or if they were there is inadequate evidence for how the risk was assessed, managed, documented and ultimately resolved.   

E6(R2) Addendum Solutions: How CROs Are Helping

Fortunately, SMBs can turn to their CROs for help. An effective CRO partner should be able to oversee much of the burden of implementing an E6(R2) by conducting a comprehensive risk assessment and designing and implementing a compliant RBM system for their clients. However, sponsors have to bring CROs to the table early in the process so that study design can be built around an RBM solution – rather than trying to force fit a solution once the study is in motion.

When selecting a CRO who can deliver an E6(R2) solution, sponsors should look for partners who can demonstrate the following:

E6(R2) Expertise. The vendor’s client team should have a deep understanding of the E6(R2) addendum and be able to provide guidance and SOPs on how to comply from day one. They should provide support in conducting protocol risk assessments during study design, help the sponsors identify gaps in their current risk identification process, and develop quality management plans, including key reporting indicators (KRIs) that can be used to customize the data management solution for the ongoing monitoring needs of each site.

Technology: The vendor should provide a centralized RBM data management platform that can capture all risk monitoring data in a single location and be customized to provide alerts and reminders when data is missing or needed, or when outliers are discovered. The platform should replace manual reporting processes and provide dashboards that generate real-time insights into the risk environment across all sites.

Training. A good vendor will provide training for all CRAs and relevant site staff on how to use the RBM platform and processes in the trial environment. As Patricia Leuchten, President and CEO of The Avoca Group, stated in this KNECT365 article: “The easy part is creating processes, getting SOPs aligned, insuring there’s a strength of documentation. The hard part is getting individuals to change their behaviors and mindset as it pertains to executing trials through the lens of risk.” Culture change is a significant aspect of RBM adoption, so this training is critical for success.

Proof it works. The vendor should provide case studies and client contacts to demonstrate past successes. These examples should include details on how the transition worked, and what time and cost benefits were delivered. Sponsors can use these case studies to vet vendors, and to convince internal stakeholders of the benefits of adopting an RBM approach.

E6(R2) isn’t going away. If SMBs want to avoid the time, cost, and uncertainty of audit findings related to clinical research oversight they need to move forward with this transition. Finding a vendor who can provide the necessary technology and expertise can ease the challenge of adoption and ensure monitoring strategies maximize the benefits while meeting compliance requirements.

           

See also: Scope 2019: Risk-Based Monitoring Delivers Big On Quality

Written by:
Cheryle Evans
Senior Vice President of Clinical Operations

Advanced Clinical
Advanced Clinical_Cheryle Evans-circle thumbnail
Connect with Cheryle on LinkedIn
Cheryle is a senior-level executive with extensive, progressive clinical research experience. She is responsible for the strategic planning and tactical operations in project management, clinical monitoring, site activation, safety, and document management. She has led global teams across multiple disciplines, successfully utilizing automation to improve quality and streamline operations. Prior to joining Advanced Clinical in 2013, Cheryle was the VP of Clinical Monitoring, NA, with inVentiv Health Clinical, where she led the optimization of three Global Strategic Units: Global Study Start-Up, Expedited Safety Reporting, and Document Management and Publishing. Prior to her tenure with inVentiv Health Clinical, Cheryle was part of a strategic team with Essential CRO, where she supported the transition and growth from a Site Management Organization to a top-five, global, full-service CRO. Cheryle has therapeutic expertise in cardiovascular, urologic, dermatologic, and women’s/men’s health clinical trials.

MEET US AT DIA

 

Tags: Clinical Research, Standard Operating Procedures, E6(R2) Addendum, Risk Assessment, Biopharma